Cargando…

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunetti, Oronzo, Gnoni, Antonio, Licchetta, Antonella, Longo, Vito, Calabrese, Angela, Argentiero, Antonella, Delcuratolo, Sabina, Solimando, Antonio Giovanni, Casadei-Gardini, Andrea, Silvestris, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843290/ https://www.ncbi.nlm.nih.gov/pubmed/31640191 http://dx.doi.org/10.3390/medicina55100707

Ejemplares similares

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Longo, Vito, et al.
Publicado: (2019)

Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
por: Gnoni, Antonio, et al.
Publicado: (2019)

Immune system and bone microenvironment: rationale for targeted cancer therapies
por: Gnoni, Antonio, et al.
Publicado: (2020)

Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
por: Argentiero, Antonella, et al.
Publicado: (2020)

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Immunotherapeutic approaches for hepatocellular carcinoma
por: Longo, Vito, et al.
Publicado: (2017)

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview
por: Argentiero, Antonella, et al.
Publicado: (2019)

Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review
por: Argentiero, Antonella, et al.
Publicado: (2019)

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
por: Argentiero, Antonella, et al.
Publicado: (2020)

Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions
por: Gnoni, Antonio, et al.
Publicado: (2013)

MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
por: Brunetti, Oronzo, et al.
Publicado: (2015)

Angiogenesis in adenosquamous cancer of pancreas
por: Silvestris, Nicola, et al.
Publicado: (2017)

A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery
por: Shadbad, Mahdi Abdoli, et al.
Publicado: (2021)

Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue
por: Longo, Vito, et al.
Publicado: (2016)

Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
por: Solimando, Antonio Giovanni, et al.
Publicado: (2021)

Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
por: Argentiero, Antonella, et al.
Publicado: (2019)

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era
por: Burgaletto, Chiara, et al.
Publicado: (2021)

Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy
por: Fasano, Rossella, et al.
Publicado: (2021)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside
por: Solimando, Antonio G., et al.
Publicado: (2020)

A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report
por: De Summa, Simona, et al.
Publicado: (2021)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
por: Brunetti, Oronzo, et al.
Publicado: (2019)

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2022)

Corrigendum: Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2023)

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
por: Leone, Patrizia, et al.
Publicado: (2021)

Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection
por: Paradiso, Angelo Virgilio, et al.
Publicado: (2020)

CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
por: Porcelli, Letizia, et al.
Publicado: (2019)

Actors on the Scene: Immune Cells in the Myeloma Niche
por: Leone, Patrizia, et al.
Publicado: (2020)

Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and Development of Colorectal Cancer: Time to Overcome the Challenging Barriers?
por: Gholizadeh, Mahsa, et al.
Publicado: (2021)

Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare
por: Silvestris, Nicola, et al.
Publicado: (2022)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

Gene Expression Comparison between Alcohol-Exposed versus Not Exposed Pancreatic Ductal Adenocarcinoma Patients Reveals a Peculiar TGFβ-Related Phenotype: An Exploratory Analysis
por: Doronzo, Antonio, et al.
Publicado: (2023)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
por: Makaremi, Shima, et al.
Publicado: (2021)

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
por: Longo, Vito, et al.
Publicado: (2019)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jj7k8f7d76sa4uu33d78uiibdu